Research programme: stem cell modulators - Boston BiomedicalAlternative Names: Cancer stem cell pathway inhibitor - Boston Biomedical; Cancer stemness kinase inhibitor - Boston Biomedical; Stem cell modulating cancer therapeutics - Boston Biomedical
Latest Information Update: 14 Sep 2016
At a glance
- Originator Boston Biomedical
- Class Antineoplastics
- Mechanism of Action Phosphotransferase inhibitors; Signal transduction pathway inhibitors; Stem cell inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Sep 2016 Preclinical trials in Cancer in USA (Parenteral) before September 2016